Tidal Investments LLC grew its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 633.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,841 shares of the medical research company's stock after purchasing an additional 37,861 shares during the period. Tidal Investments LLC's holdings in IQVIA were worth $8,615,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of IQV. Norges Bank acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $336,041,000. Raymond James Financial Inc. acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $236,120,000. American Century Companies Inc. increased its holdings in shares of IQVIA by 396.0% in the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after purchasing an additional 905,960 shares during the period. Invesco Ltd. boosted its stake in shares of IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after buying an additional 902,226 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of IQVIA by 20.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after buying an additional 712,958 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
IQVIA Trading Down 0.8%
Shares of IQV stock traded down $1.08 during mid-day trading on Friday, hitting $136.96. 2,248,506 shares of the company's stock were exchanged, compared to its average volume of 1,560,203. The stock has a market cap of $23.69 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 1.99 and a beta of 1.34. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The stock has a 50-day simple moving average of $155.33 and a two-hundred day simple moving average of $183.37.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the prior year, the company posted $2.54 EPS. The company's quarterly revenue was up 2.5% compared to the same quarter last year. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the company. Hsbc Global Res downgraded IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. JPMorgan Chase & Co. decreased their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Robert W. Baird decreased their price target on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Royal Bank of Canada restated an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Finally, Citigroup restated a "neutral" rating on shares of IQVIA in a research note on Thursday. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $228.14.
View Our Latest Stock Analysis on IQV
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
